» Articles » PMID: 17023670

Leptin Antagonist Reveals That the Normalization of Caloric Intake and the Thermic Effect of Food After High-fat Feeding Are Leptin Dependent

Overview
Specialty Physiology
Date 2006 Oct 7
PMID 17023670
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

High-fat (HF) feeding induces a transient increase in caloric intake and enhances energy expenditure. We hypothesized that leptin is necessary for homeostatic restoration of the HF-enhanced caloric intake and may mediate the increase in uncoupling protein-1 (UCP1) in brown adipose tissue (BAT). We employed a leptin antagonist to examine the role of leptin in these biological processes. Simultaneous central administration of leptin and increasing doses of the leptin antagonist revealed a dose-dependent inhibition of leptin-induced hypothalamic signal transducer and activator of transcription-3 phosphorylation, and 7 days of infusion of the leptin antagonist produced the predicted increase in food intake and weight gain. When delivered with exogenous leptin in a 7-day infusion, the leptin antagonist blocked leptin-mediated anorexic effects as well as the increase in BAT UCP1 protein and signal transducer and activator of transcription-3 phosphorylation. Rats were then fed an HF diet (60% kcal as fat) or chow and simultaneously infused with antagonist (25 microg/day into the lateral ventricle) for 7 days and compared with vehicle-infused chow-fed rats. Daily caloric intake of both HF groups peaked on day 2. HF feeding elevated caloric intake, which nearly normalized by day 7, whereas in the presence of the antagonist, caloric intake remained elevated. Moreover, the HF-mediated augmentation in UCP1 in BAT was prevented by the antagonist. These results demonstrate that leptin is essential for the homeostatic restoration of caloric intake after HF feeding and that this leptin antagonist is able to block central leptin signaling and leptin-mediated UCP1 elevation.

Citing Articles

Rules for body fat interventions based on an operating point mechanism.

Bar A, Karin O, Mayo A, Ben-Zvi D, Alon U iScience. 2023; 26(2):106047.

PMID: 36818281 PMC: 9929596. DOI: 10.1016/j.isci.2023.106047.


Peripheral versus central insulin and leptin resistance: Role in metabolic disorders, cognition, and neuropsychiatric diseases.

Erichsen J, Fadel J, Reagan L Neuropharmacology. 2021; 203:108877.

PMID: 34762922 PMC: 8642294. DOI: 10.1016/j.neuropharm.2021.108877.


A Leptin Receptor Antagonist Attenuates Adipose Tissue Browning and Muscle Wasting in Infantile Nephropathic Cystinosis-Associated Cachexia.

Gonzalez A, Cheung W, Perens E, Oliveira E, Gertler A, Mak R Cells. 2021; 10(8).

PMID: 34440723 PMC: 8393983. DOI: 10.3390/cells10081954.


Brain leptin reduces liver lipids by increasing hepatic triglyceride secretion and lowering lipogenesis.

Hackl M, Furnsinn C, Schuh C, Krssak M, Carli F, Guerra S Nat Commun. 2019; 10(1):2717.

PMID: 31222048 PMC: 6586634. DOI: 10.1038/s41467-019-10684-1.


Epiregulin induces leptin secretion and energy expenditure in high-fat diet-fed mice.

Yasmeen R, Shen Q, Lee A, Leung J, Kowdley D, DiSilvestro D J Endocrinol. 2018; 239(3):377-388.

PMID: 30400011 PMC: 6226053. DOI: 10.1530/JOE-18-0289.